SG11201907744QA - Replacement of cytotoxic preconditioning before cellular immunotherapy - Google Patents

Replacement of cytotoxic preconditioning before cellular immunotherapy

Info

Publication number
SG11201907744QA
SG11201907744QA SG11201907744QA SG11201907744QA SG11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA
Authority
SG
Singapore
Prior art keywords
international
pct
cytotoxic preconditioning
cellular
cytotoxic
Prior art date
Application number
SG11201907744QA
Inventor
Theresa Ann Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of SG11201907744QA publication Critical patent/SG11201907744QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

ACTBIND IGFICHE DECREASE ACT SWUNG NICHE CO*{: ANT/ age ,1 a i0 t%) Ermr bAr, SEA hF 4r! mtr, nor (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ill~~~~~~~~ 011101010VIIIOH olo HE mil moiolommo oimIE (10) International Publication Number WO 2018/183927 Al N cr (51) International Patent Classification: A61K 45/00 (2006.01) A61P 35/00 (2006.01) A61K 31/573 (2006.01) (21) International Application Number: PCT/US2018/025517 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/480,414 01 April 2017 (01.04.2017) US 62/613,697 04 January 2018 (04.01.2018) US 62/624,454 31 January 2018 (31.01.2018) US (71) Applicant: AVM BIOTECHNOLOGY, LLC [US/US]; 1749 Dexter Avenue N, Seattle, WA 98109 (US). (72) Inventor: DEISHER, Theresa Ann; 8226 23rd Ave NE., Seattle, WA 98115 (US). (74) Agent: BAUMGARTNER, Marc; Baumgartner Patent Law, 3344 NE 30th Ave, Portland, OR 97212 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY Figure 1 CONTROL 1s 114.9 MG/ DEX MED 9.3 NIGIKG1 c)1: 1-1 (57) : Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. More specifically the c)1: 1-1 compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunother- apy is bound and sequestered, without the use of cytotoxic preconditioning. O [Continued on next page] WO 2018/183927 Al MIDEDIMOIMEMIEHNOMOINIIIMEIDEHMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201907744QA 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy SG11201907744QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762480414P 2017-04-01 2017-04-01
US201862613697P 2018-01-04 2018-01-04
US201862624454P 2018-01-31 2018-01-31
PCT/US2018/025517 WO2018183927A1 (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Publications (1)

Publication Number Publication Date
SG11201907744QA true SG11201907744QA (en) 2019-09-27

Family

ID=62111173

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907744QA SG11201907744QA (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Country Status (13)

Country Link
US (2) US11219628B2 (en)
EP (1) EP3490605B1 (en)
JP (2) JP6748221B2 (en)
KR (1) KR102509006B1 (en)
CN (1) CN110475571B (en)
AU (1) AU2018243753A1 (en)
BR (1) BR112019020214A2 (en)
CA (1) CA3054443A1 (en)
ES (1) ES2954311T3 (en)
IL (1) IL269209B2 (en)
MX (1) MX2019011679A (en)
SG (1) SG11201907744QA (en)
WO (1) WO2018183927A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
CN110475571B (en) 2017-04-01 2023-04-04 Avm生物技术有限责任公司 Replacement for cellular immunotherapy pre-conditioning for cytotoxicity
JP7414529B2 (en) 2017-06-07 2024-01-16 シファメド・ホールディングス・エルエルシー Intravascular fluid transfer devices, systems, and methods of use
WO2019094963A1 (en) 2017-11-13 2019-05-16 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
US10722631B2 (en) 2018-02-01 2020-07-28 Shifamed Holdings, Llc Intravascular blood pumps and methods of use and manufacture
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
CN111918645A (en) * 2018-11-14 2020-11-10 Avm生物技术有限责任公司 Stable glucocorticoid formulations
US20220016168A1 (en) * 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
US20210161959A1 (en) * 2019-11-06 2021-06-03 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
CN113189340A (en) * 2020-01-14 2021-07-30 中国医学科学院基础医学研究所 Use of cellular apoptosis pathway in cell therapy
EP4106775A4 (en) * 2020-02-20 2024-03-06 Kite Pharma Inc Chimeric antigen receptor t cell therapy
EP4110902A1 (en) 2020-02-28 2023-01-04 AVM Biotechnology, LLC Lypmphocyte population and methods for producing same
US20230136350A1 (en) * 2020-04-10 2023-05-04 North Carolina State University Enhanced viral transduction of mammalian cells using material scaffolds
CN111443210B (en) * 2020-04-10 2023-09-22 青海大学附属医院 Bubble type echinococcosis early diagnosis and treatment biomarker and application thereof
US20230172950A1 (en) 2020-04-29 2023-06-08 Avm Biotechnology, Llc Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus
AU2020451285A1 (en) 2020-06-01 2022-12-22 Avm Biotechnology, Llc Methods of treatment using ICAM-modulating agents
WO2022049572A1 (en) * 2020-09-01 2022-03-10 The National Institute for Biotechnology in the Negev Ltd. Immune system restoration by cell therapy
CN113322233A (en) * 2021-04-19 2021-08-31 格源致善(上海)生物科技有限公司 Improved preparation method and application of reactive T cells based on neoantigens
CN116063401B (en) * 2021-08-13 2023-12-01 中国人民解放军总医院 Blocking type PD-L1 targeted ultra-high affinity small protein and application thereof
WO2023034377A1 (en) 2021-09-01 2023-03-09 Avm Biotechnology, Llc Lymphocyte population and methods for producing same
CN114031678A (en) * 2021-12-08 2022-02-11 中国科学院新疆理化技术研究所 Preparation method and application of polypeptide component of scorpion venom polypeptide
CN115785203B (en) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 Lung cancer specific molecular target 10 and application thereof
CN116606352B (en) * 2023-07-14 2023-09-29 诺赛联合(北京)生物医学科技有限公司 Application of composition gel with antibacterial and repairing functions in gynecological diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
ES2320314T3 (en) 1997-12-16 2009-05-21 University Of Zurich DIAGNOSIS FOR TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
WO2003077865A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
CN103393681B (en) 2002-05-17 2017-04-12 细胞基因公司 Methodand composition for treatment and management of multiple myeloma
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
JP5129122B2 (en) * 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー Combination of antibodies and glucocorticoids for cancer treatment
JP4997239B2 (en) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 Anti-CD26 antibody and method of use thereof
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US20100247491A1 (en) 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
KR101679084B1 (en) * 2008-05-23 2016-11-24 아고스 쎄라퓨틱스, 인코포레이티드 Novel soluble cd83 polypeptides, formulations and methods of use
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2009152187A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
KR101833204B1 (en) * 2010-08-18 2018-03-02 테레사 데이셔 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
EP3305798A1 (en) 2010-12-09 2018-04-11 The Trustees of The University of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2824997C (en) 2011-01-18 2023-01-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
KR20140060541A (en) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Rna engineered t cells for the treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
DK3129470T3 (en) * 2014-04-07 2021-07-05 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
AU2016212162A1 (en) * 2015-01-26 2017-07-13 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to CD123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
JP7197979B2 (en) 2015-05-28 2022-12-28 カイト ファーマ インコーポレイテッド Methods of conditioning a patient for T cell therapy
CA3044261A1 (en) * 2016-11-30 2018-06-07 Intrexon Corporation Steroid administration and immunotherapy
CN110475571B (en) 2017-04-01 2023-04-04 Avm生物技术有限责任公司 Replacement for cellular immunotherapy pre-conditioning for cytotoxicity

Also Published As

Publication number Publication date
JP6748221B2 (en) 2020-08-26
MX2019011679A (en) 2019-11-01
BR112019020214A2 (en) 2020-04-22
US20180296572A1 (en) 2018-10-18
EP3490605B1 (en) 2023-06-07
CA3054443A1 (en) 2018-10-14
ES2954311T3 (en) 2023-11-21
IL269209B2 (en) 2023-11-01
JP2019515888A (en) 2019-06-13
EP3490605A1 (en) 2019-06-05
IL269209B1 (en) 2023-07-01
IL269209A (en) 2019-11-28
WO2018183927A1 (en) 2018-10-04
KR20190130624A (en) 2019-11-22
US20220160729A1 (en) 2022-05-26
CN110475571B (en) 2023-04-04
KR102509006B1 (en) 2023-03-13
CN110475571A (en) 2019-11-19
AU2018243753A1 (en) 2019-10-10
JP7162632B2 (en) 2022-10-28
EP3490605C0 (en) 2023-06-07
JP2020114837A (en) 2020-07-30
US11219628B2 (en) 2022-01-11

Similar Documents

Publication Publication Date Title
SG11201907744QA (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201811074RA (en) Nant cancer vaccine
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201808108XA (en) Synthesis of indazoles
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201407200TA (en) Liquid formulation
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201805001UA (en) Method of treating influenza a
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900043TA (en) Antibody formulations
SG11201900361RA (en) Methods of treating prostate cancer
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201809882XA (en) Pharmaceutical combinations for treating cancer